Human Growth Hormone Fragment 176–191 (hGH frag 176–191) is a peptide fragment of human growth hormone. It has erroneously been presented as a lipolytic peptide fragment based on extrapolations of clinical data pertaining to AOD9604, a modified form of hGH frag 176–191. In contrast to AOD9604, hGH frag 176–191 has not been studied in humans.[1]
Names | |
---|---|
Other names
H-Phe-Leu-Arg-Ile-Val-Gln-Cys(1)-Arg-Ser-Val-Glu-Gly-Ser-Cys(1)-Gly-Phe-OH
| |
Identifiers | |
3D model (JSmol)
|
|
| |
| |
Properties | |
C78H123N23O22S2 | |
Molar mass | 1799.10 g·mol−1 |
Related compounds | |
Related compounds
|
AOD9604 |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
References
edit- ^ "Human Growth Hormone Fragment 176-191 - Search Results - PubMed". PubMed. Retrieved 2023-12-23.
Extra reading
edit- Habibullah, Mahmoud M; Mohan, Syam; Syed, Nabeel Kashan; Makeen, Hafiz A; Jamal, Qazi Mohammad Sajid; Alothaid, Hani; Bantun, Farkad; Alhazmi, Alaa; Hakamy, Ali; Kaabi, Yahia A; Samlan, Ghalia; Lohani, Mohtashim; Thangavel, Neelaveni; Al-Kasim, Mohamed Ahmed (June 2022). "Human Growth Hormone Fragment 176–191 Peptide Enhances the Toxicity of Doxorubicin-Loaded Chitosan Nanoparticles Against MCF-7 Breast Cancer Cells". Drug Design, Development and Therapy. 16: 1963–1974. doi:10.2147/DDDT.S367586. PMC 9249349. PMID 35783198.